Infections

All Conditions

Nervous System Diseases

Nutritional and Metabolic Diseases

Symptoms and General Pathology

Neoplasms

Digestive System Diseases

Rare Diseases

Tetanus

Tetany

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

All Drugs and Chemicals

Immunomodulating Agents

CEA pulsed dendritic cells

Wei-Lan Yu, R.N.

Jacqueline Whang-Peng, M.D.

Hui-Ju Ch'ang, M.D.

Ann-Li Cheng, M.D.

Ko-Jiunn Liu, Ph.D.

The specific aims of this study are as follows:

1. Primary endpoint: to evaluate the clinical responses of vaccinated patients.
2. Secondary endpoint: to evaluate the safety of this treatment and the immune responses against CEA before and after the treatment

In this trial, we will immunize metastatic colorectal cancer patients with recombinant CEA-pulsed DCs mixed with tetanus toxoid by subcutaneous injection. Low dose IL-2 will be given subcutaneously following DC vaccination to boost the growth of T cells. We will adapt "Simon's optimal two-stage design" for this study. In the first stage, we will treat 12 patients to evaluate the safety of this new protocol. If there are no severe toxicities/side effects and there is at least one patient that had stable disease or better clinical response, then we will proceed to the second stage and treat additional 25 patients. We will follow the clinical outcome of these 37 patients. The immune responses against CEA before and after vaccination will be examined.

Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment

A Phase I/II Clinical Study of Immunotherapy for Advanced Colorectal Cancers Using CEA-Pulsed Dendritic Cells Mixed With Tetanus Toxoid and Subsequent IL-2 Treatment

National Health Research Institutes, Taiwan

National Taiwan University Hospital

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment	NCT00154713	Colorectal Canc...	CEA pulsed dend...	20 Years - 75 Years	National Taiwan University Hospital
Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment	NCT00154713	Colorectal Canc...	CEA pulsed dend...	20 Years - 75 Years	National Taiwan University Hospital

Spots Global Cancer Trial Database for cea pulsed dendritic cells